Renin-Angiotensin-Aldosterone System Inhibition and Mineralocorticoid Receptor Antagonists: The Overriding Importance of Enablers and Dampers.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Emerging Strategies for Cardio-Renal Protection Beyond RAAS Blockade:Saudi medical journal · 2026
   Review
2. Exploring the biological basis for the identification of different syndromes in ischemic heart failure based on joint multi-omics analysis.Frontiers in pharmacology · 2025
   Article
3. The Mineralocorticoid Receptor in the Vasculature: Friend or Foe?Annual review of physiology · 2024
   Review
4. Edema formation in congestive heart failure and the underlying mechanisms.Frontiers in cardiovascular medicine · 2022
   Review
5. Optimization of RAASi Therapy with New Potassium Binders for Patients with Heart Failure and Hyperkalemia: Rapid Review and Meta-Analysis.Journal of clinical medicine · 2021
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.